Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.

Background: Inflammatory bowel disease (IBD) is a relapsing-remitting illness requiring proactive monitoring of gut inflammation. We aimed to determine the correlations of plasma myeloperoxidase (pMPO) and calprotectin (pCal), two neutrophil proteins, with existing measures of disease activity.

Methods: Adults with IBD undergoing ileocolonoscopy were recruited prospectively.

Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease.

Background: Concentrations of the neutrophil protein myeloperoxidase are elevated in the feces of individuals with endoscopically active inflammatory bowel disease (IBD). Its enzyme activity could give an immediate readout of endoscopic inflammation. We investigated whether fecal myeloperoxidase activity (fMPOa) is associated with IBD endoscopic inflammation.

Fecal Myeloperoxidase Levels Reflect Disease Activity in Children With Crohn's Disease.

Background: Crohn's disease (CD) is a major form of inflammatory bowel disease (IBD) which has relapsing and remitting symptoms. Better ways to detect and monitor active disease are required for early diagnosis and optimal outcomes. We assessed fecal myeloperoxidase (fMPO), a neutrophil-derived enzyme that produces hypochlorous acid, as a marker of disease activity in children with CD.

Perianal Crohn's disease: Still more questions than answers.

In this editorial we comment on the article by Pacheco published in a recent issue of the . We focus specifically on the burden of illness associated with perianal fistulizing Crohn's disease (PFCD) and the diagnostic and therapeutic challenges in the management of this condition. Evolving evidence has shifted the diagnostic framework for PFCD from anatomical classification systems, to one that is more nuanced and patient-focused to drive ongoing decision making.

Development and investigation of a non-invasive disease severity index for inflammatory bowel disease.

Introduction: The disease severity index (DSI) encapsulates the inflammatory bowel disease (IBD) burden but requires endoscopic investigations. This study developed a non-invasive DSI using faecal calprotectin (DSI-fCal) and faecal myeloperoxidase (DSI-fMPO) instead of colonoscopy.

Methods: Adults with IBD were recruited prospectively.

The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.

Background: The disease severity index (DSI) for inflammatory bowel disease (IBD) combines measures of disease phenotype, inflammatory activity, and patient-reported outcomes. We aimed to validate the DSI and assess its utility in predicting a complicated IBD course.

Methods: A multicenter cohort of adults with IBD was recruited.

The Impact of Disease Activity on Sexual and Erectile Dysfunction in Patients With Inflammatory Bowel Disease.

Background: Increased disease activity may be a risk factor for sexual dysfunction (SD) in patients with inflammatory bowel disease (IBD). This study investigated associations between objective measures of disease activity and sexual function.

Methods: Adults with IBD undergoing ileocolonoscopy were prospectively recruited.

Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.

Background And Aims: Inflammatory bowel disease [IBD], consisting of Crohn's disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal myeloperoxidase [fMPO], a neutrophil granule enzyme, as a biomarker of IBD activity.

The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course.

Background: The Disease Severity Index (DSI) is a novel tool to predict disease severity in inflammatory bowel disease (IBD). However, its ability to predict disease complications and the presence of psychosocial comorbidity is unclear.

Aims: To assess prospectively associations between the DSI and psychological symptoms, quality-of-life (QoL) and disease outcomes in an IBD cohort.

The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.

Background: Disease activity may be a risk factor for psychological illness in patients with inflammatory bowel disease (IBD).

Aim: To correlate objective measures of disease activity with psychological symptoms.

Methods: Adult patients with IBD undergoing ileocolonoscopy were prospectively recruited.

The IBD-Cope: A New Instrument for Measuring Coping in Inflammatory Bowel Disease Patients.

Background And Aims: Inflammatory bowel disease (IBD) has a major impact on psychological well-being. How an individual copes with IBD determines quality of life. We aimed to develop a brief, IBD-specific questionnaire to assess coping strategies (IBD-Cope) and to determine its test-retest reliability and validity.

What is the lower limit for postprandial venous plasma glucose in healthy young adults?

Background: There is general agreement that the lower limit for postprandial venous plasma glucose is the same or higher than for a fasted sample. The finding of a postprandial fall in glucose would therefore have implications for assignment of the lower limit of the normal glucose range.

Methods: An antecubital venous sample was collected before and one hour after breakfast.

Impact of prandial status on the comparison of capillary glucose meter and venous plasma glucose measurements in healthy volunteers.

Background: There is a negative glucose gradient between the capillary and venous systems, produced by glucose uptake into peripheral tissues. This gradient is augmented by oral glucose ingestion in healthy volunteers; thus prandial status may impact on capillary glucose meter performance. Our primary aim was to investigate whether the (capillary-venous plasma) glucose difference changed in relation to prandial status, in healthy volunteers.